VTRS:NSD-Viatris Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.53

Change

-0.35 (-3.22)%

Market Cap

USD 13.29B

Volume

7.97M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 80.66B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.46B
HLN Haleon plc

N/A

USD 39.18B
TEVA Teva Pharma Industries Ltd ADR

N/A

USD 19.64B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.67B
CTLT Catalent Inc

N/A

USD 10.02B
ELAN Elanco Animal Health

N/A

USD 9.03B
PRGO Perrigo Company PLC

N/A

USD 3.85B
PBH Prestige Brand Holdings Inc

N/A

USD 3.33B
EVT Eaton Vance Tax Advantaged Div..

N/A

USD 3.26B

ETFs Containing VTRS

DUSA 4.07 % 0.63 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 4.01 % 0.42 %

N/A

USD 0.69B
MVPA MVPA 3.85 % 0.00 %

N/A

USD 0.05B
XLVE:CA Mulvihill U.S. Health Car.. 1.69 % 0.00 %

N/A

CAD 7.08M
CVY Invesco Zacks Multi-Asset.. 1.04 % 0.65 %

N/A

USD 0.12B
UMI:CA CI WisdomTree U.S. MidCap.. 0.99 % 0.41 %

N/A

CAD 0.02B
DON WisdomTree U.S. MidCap Di.. 0.90 % 0.38 %

N/A

USD 3.50B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 9.66M
RPV Invesco S&P 500® Pure Va.. 0.00 % 0.35 %

N/A

USD 2.02B
XXM:CA 0.00 % 0.68 %

N/A

N/A
XMMD:LSE Xtrackers - MSCI Emerging.. 0.00 % 0.00 %

N/A

USD 0.67B
UMI-B:CA CI WisdomTree U.S. MidCap.. 0.00 % 0.00 %

N/A

CAD 0.03B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.77% 44% F 27% F
Dividend Return 2.22% 80% B- 74% C
Total Return -0.55% 44% F 31% F
Trailing 12 Months  
Capital Gain 16.61% 67% D+ 63% D
Dividend Return 5.32% 83% B 69% C-
Total Return 21.93% 67% D+ 67% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.32% 47% F 28% F
Dividend Return -6.01% 47% F 30% F
Total Return 2.31% 67% D+ 53% F
Risk Return Profile  
Volatility (Standard Deviation) 15.08% 99% N/A 82% B
Risk Adjusted Return -39.87% 41% F 23% F
Market Capitalization 13.29B 78% C+ 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector